Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva N Hadaschik

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Human Immunology|June 28, 2015
TGF-β1-induced regulatory T cellsEva N Hadaschik, Alexander H Enk
International Journal of Dermatology|November 9, 2015
Altered expression of keratin 14 in lesional epidermis of autoimmune skin diseasesXiaoying Wei, Katharina Fricker, Alexander H Enk, et al.
Acta Dermato-Venereologica|February 23, 2017
Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and UstekinumabJochen H Hoffmann, Christian Knoop, Alexander H Enk, et al.
Acta Dermato-Venereologica|September 30, 2021
Detailed Long-term Dynamics of Neutrophil-to-Lymphocyte Ratio under Biologic Treatment Reveals Differential Effects of Tumour Necrosis Factor-alpha and Interleukin 12/23 AntagonistsJochen H O Hoffmann, Christian Knoop, Alexander Enk, et al.
Acta Dermato-Venereologica|October 18, 2012
Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse eventsVera Seidling, Jochen H O Hoffmann, Alexander H Enk, et al.
Dermatologic Therapy|August 24, 2016
Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoidRoland Schneiderbauer, Stefanie Martinache, Monika Engstner, et al.
Journal of Dermatological Science|October 13, 2014
Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patientsJochen H O Hoffmann, Christian Knoop, Alexander H Enk, et al.
Acta Dermato-Venereologica|April 27, 2021
Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio-markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment CyclesJochen H O Hoffmann, Christian Knoop, Knut Schäkel, et al.
The Journal of Dermatology|January 20, 2021
Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)-α antagonists versus TNF-α antagonists alone in psoriatic patientsJochen H O Hoffmann, Christian Knoop, Kunt Schäkel, et al.
Experimental Dermatology|June 17, 2016
Interindividual variation of NETosis in healthy donors: introduction and application of a refined method for extracellular trap quantificationJochen H O Hoffmann, Knut Schaekel, Maria R Gaiser, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Human Immunology|June 28, 2015
TGF-β1-induced regulatory T cellsEva N Hadaschik, Alexander H Enk
International Journal of Dermatology|November 9, 2015
Altered expression of keratin 14 in lesional epidermis of autoimmune skin diseasesXiaoying Wei, Katharina Fricker, Alexander H Enk, et al.
Acta Dermato-Venereologica|February 23, 2017
Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and UstekinumabJochen H Hoffmann, Christian Knoop, Alexander H Enk, et al.
Acta Dermato-Venereologica|September 30, 2021
Detailed Long-term Dynamics of Neutrophil-to-Lymphocyte Ratio under Biologic Treatment Reveals Differential Effects of Tumour Necrosis Factor-alpha and Interleukin 12/23 AntagonistsJochen H O Hoffmann, Christian Knoop, Alexander Enk, et al.
Acta Dermato-Venereologica|October 18, 2012
Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse eventsVera Seidling, Jochen H O Hoffmann, Alexander H Enk, et al.
Dermatologic Therapy|August 24, 2016
Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoidRoland Schneiderbauer, Stefanie Martinache, Monika Engstner, et al.
Journal of Dermatological Science|October 13, 2014
Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patientsJochen H O Hoffmann, Christian Knoop, Alexander H Enk, et al.
Acta Dermato-Venereologica|April 27, 2021
Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio-markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment CyclesJochen H O Hoffmann, Christian Knoop, Knut Schäkel, et al.
The Journal of Dermatology|January 20, 2021
Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)-α antagonists versus TNF-α antagonists alone in psoriatic patientsJochen H O Hoffmann, Christian Knoop, Kunt Schäkel, et al.
Experimental Dermatology|June 17, 2016
Interindividual variation of NETosis in healthy donors: introduction and application of a refined method for extracellular trap quantificationJochen H O Hoffmann, Knut Schaekel, Maria R Gaiser, et al.
Pageof 2